Low molecular weight heparins in the management of unstable angina/ non-q-wave myocardial infarction

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 113-121

  Cohen, Marc ^a,b  

^a Halmemann Hospital   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

Enoxaparin; Low molecular weight heparin; Non q wave myocardial infarction; Unfractionated heparin; Unstable angina

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ANTICOAGULANT THERAPY; CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANIMALS; CLINICAL TRIALS; DISEASE MANAGEMENT; DRUG EVALUATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION;

EID: 0032750367     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute ischémie syndromes. Circulation 1988;77:1213-1220
2. Davies MJ, Thomas A. Plaque fissuring: The cause of acute myocardial infarction, sudden ischémie death, and crescendo angina. Br Heart J 1985;53:363-373
3. Caims JA, Lewis HD, Meade TW, et al. Antithrombotic agents in coronary artery disease. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995;108 (Suppl 4): 380S-400S
4. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337: 447-452
5. Antman EM, McCabe CH, Premmereur J, et al. Enoxaparin for the acute and chronic management of unstable angina/non-Qwave myocardial infarction: Results of TIMI 11B. Circulation 1998;9S(Suppl):I504
6. Wallentin L, Ohlsson J, Swahn E , et al. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568
7. Klein W, Buchwald A, Hillis S, et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 1997;96:61-68
8. Leizorovicz A. PRAXIS: Fraxiparine in ischémie syndromes. Presentation at the European Society of Cardiology. Vienna, August, 1998
9. Goodman S, Bigzoni F, Radley D, et al. One-year follow-up of the ESSENCE trial (enoxaparin versus unfractionated heparin in unstable angina and non-Q-wave myocardial infarction). European Society of Cardiology, Vienna Meeting Abstract 1998;P477
10. Cohen M. Effect of low molecular weight heparin on prespecified patient subgroups with rest unstable angina or non-Q-wave myocardial infarction. American Heart Association 1998; Abstract: 2945
11. Fox K, Bosanquet N. Cost implications of replacing standard heparin with low molecular weight heparin in unstable coronary artery disease. Br Med J 1998;5:92-105
12. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial. Circulation 1998;97:1702-1707
13. Antman EM, Cohen M, Radley D, et al. Enoxaparin for unstable angina/non-Q-wave myocardial infarction: Meta-analysis of TIMI11B and ESSENCE. J Am Coll Cardiol 1999 33: A819-1
14. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26: 313-318
15. Yusuf S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998;352:507-514
16. Antman E, for the TIMI 11A investigators. Dose ranging trial of enoxaparin for unstable angina: Results of TIMI 11 A. J Am Coll Cardiol 1997;29:I474-1482
17. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin. Circulation 1998;98:294-299
18. Antman EM, Handin R. Low molecular weight heparins: An intriguing new twist with profound implications. Circulation 1998;98:287-289
19. Broze GR Jr. The tissue factor pathway of coagulation. In: Loscalzo J, Shafer AI, eds. Thrombosis and Hemorrhage. Boston, Mass: Blackwell Scientific Publications;1994:57-86
20. Hoppensteadt DA, Jeske W, Farced J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low molecular weight heparin. Blood Coag Fibrinolysis 1995;6:S57-S64